The biotech industry is ripe with great investment opportunities due to technological advancements such as artificial ...

Imagine a breakthrough in cancer treatment where only malignant cells are targeted, sparing healthy host cells; or patients ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Using protein structure prediction tools, researchers have uncovered receptor structure-function relationships to improve ...

Researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin. One day, researchers want to use switches of this kind to ...

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin.

Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

Researchers have developed a new, highly effective “gene switch” to deliver targeted cell therapy. The ETH Zurich team states that this cell therapy has the potential to offer a more precise and ...

Passage Bio is outsourcing future analytical testing services in a cost-cutting move that will further cut its workforce, a ...

Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline ...

Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.